Register Now!
Find a Speaker Event
or

Results

In-person events

Tuesday, January 13, 2026
6:00 PM EST

Out-of-Office Live

Speaker:

Manuel Ozambela, MD

Location:

Meat Market, 6063 Av. Isla Verde, Carolina, PR 00979

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Wednesday, January 14, 2026
6:00 PM MST

In-Office Live

Speaker:

Katie Murray, DO, MS, FACS

Location:

Eddie V's Prime Seafood, 5111 DTC Pkwy, Greenwood Village, CO 80111

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Back to Search
INDICATION AND IMPORTANT SAFETY INFORMATION
ADSTILADRIN® (nadofaragene firadenovec-vncg) suspension, for intravesical use
INDICATION FOR USE
  • ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:
  • ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.

WARNINGS AND PRECAUTIONS
  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.

  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION:
  • Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS:
  • Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS:
  • The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

Please see full Prescribing Information.

Please see Important Safety Information and Full Prescribing Information